20 December 2023
20 December 2023
Pharmaceutical Technology outlines some of the biggest US Food and Drug Administration (FDA) drug approvals announced in 2023 that are set to make an impact in the coming years.
The life sciences sector is set to see a significant amount of change in 2024.
Kronos Bio is prioritising its multiple myeloma therapy after reviewing negative Phase Ib AML data for lanraplenib.
The FDA has requested additional information on long-term potency after the Phase II trial was first put on clinical hold due to manufacturing issues in 2022.
Merck (MSD)'s V116 vaccine is designed to prevent invasive pneumococcal disease in the adult population.
The US Food and Drug Administration (FDA) accepted the filing based on NIH-funded Phase III trial interim results, with an approval decision expected in Q1 2024.
The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.
Sanofi and Innate’s cancer collaboration agreement stretches back to 2016, with two of Sanofi’s NK cell engagers in clinical studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.
